Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It

Abbott Laboratories (ABT) is a trending stock that recently underperformed the S&P 500, returning +0.7% over the past month, though it outpaced its industry. The company reported Q1 revenues and EPS that beat consensus, and projects solid year-over-year growth with current fiscal year earnings estimated up 10.3% and revenue up 6.5%. However, earnings estimates have remained unchanged over the last 30 days, contributing to a Zacks Rank #3 (Hold) and a 'C' valuation score, suggesting near-term performance in line with the broader market.

Analysis

Abbott Laboratories (ABT) presents a mixed but fundamentally stable profile. The stock's recent performance has been modest, with a +0.7% return over the past month, underperforming the S&P 500 composite's +2.9% gain but notably outperforming its peer group, the Zacks Medical - Products industry, which declined by 3%. The company's growth outlook remains solid, with consensus estimates pointing to a +10.3% earnings per share (EPS) increase for the current fiscal year and a further +10.2% for the next. Similarly, revenue is projected to grow by +6.5% and +7.7% in the current and next fiscal years, respectively. This is supported by a recent history of operational execution, as Abbott's last reported quarter saw a +0.63% revenue surprise and a +0.8% EPS surprise, marking the third EPS beat in the last four quarters. However, a key factor tempering the outlook is the lack of upward revisions in earnings estimates over the last 30 days. This stasis is the primary driver behind its Zacks Rank #3 (Hold) rating, which suggests the stock is likely to perform in line with the broader market in the near term. The valuation appears fair, with a Zacks Value Style Score of 'C' indicating the stock is trading at par with its peers, leaving limited room for multiple expansion without new catalysts.

Key Decisions for Investors

• Given the 'Hold' rating and fair valuation, investors may consider maintaining current positions as the company's steady double-digit earnings growth provides fundamental support, despite the lack of near-term catalysts.
• Potential investors should closely monitor for upward revisions in analyst earnings estimates, as this would be a primary signal that the stock's near-term outlook is improving and could break from its expected in-line market performance.
• Note the stock's recent underperformance relative to the S&P 500, which suggests that while ABT offers stability against its struggling industry peers, it may not be a vehicle for capturing broader market upside in the current environment.